Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications
Cancer immunotherapy has shown impressive anti-tumor activity in patients with advanced and early-stage malignant tumors, thus improving long-term survival. However, current cancer immunotherapy is limited by barriers such as low tumor specificity, poor response rate, and systemic toxicities, which...
Main Authors: | Peijie Wu, Jun Han, Yanju Gong, Chao Liu, Han Yu, Na Xie |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/10/1990 |
Similar Items
-
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
by: Panagiota Economopoulou, et al.
Published: (2020-11-01) -
Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
by: Zhong-Wei Luo, et al.
Published: (2020-12-01) -
Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment
by: Hua Cheng, et al.
Published: (2024-01-01) -
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
by: Muyue Yang, et al.
Published: (2021-07-01) -
Nanoparticles mediated tumor microenvironment modulation: current advances and applications
by: Ganji Seeta Rama Raju, et al.
Published: (2022-06-01)